Futura Medical PLC Agreement with Cooper Consumer Health - Correction (4344M)
23 May 2022 - 7:35PM
UK Regulatory
TIDMFUM
RNS Number : 4344M
Futura Medical PLC
23 May 2022
23 May 2022
Futura Medical plc
("Futura" or the "Company")
RNS Correction - Futura Announces Collaboration with Cooper
Consumer Health to Commercialise MED3000 in EEA, United Kingdom and
Switzerland
Futura Medical plc (AIM: FUM), a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology and
currently focused on sexual health and pain, notes incorrect
information in the 'About Cooper Consumer Health boilerplate' in
part of its RNS announcement no: 3503M dated 23 May and restates
the relevant part of the RNS as follows:
About Cooper Consumer Health
Cooper Consumer Health is the European consolidation platform in
the self-medication (OTC) and selfcare field set up by the
investment fund Charterhouse Capital Partners in January 2016. Its
mission is to develop and market more Selfcare solutions, to more
people. It believes responsible Selfcare can contribute to lowering
the pressure on national Healthcare systems and reduce system
costs. Today, this platform has a leading position in France, the
Netherlands, Belgium, Italy, Spain, Portugal and Hong Kong. The
'Cooperation Pharmaceutique Francaise' started just outside Paris
more than 100 years ago as a cooperative between pharmacists. It
acquired Vemedia Consumer Health in 2016 and Laboratoires
Diepharmex in 2019. Meanwhile, the Group has made several brand
acquisitions across Europe, including Hexomédine, Essaven, and
Dacryoserum. The Group's main brands include Oenobiol, Valdispert,
Mag2, Pouxit, Insect Ecran, Audispray and Excilor .
www.cooperconsumerhealth.com
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile/ Zoe Bolt
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction ("ED") through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application. MED3000 is CE marked in Europe
and the UK as a clinically proven topical treatment for adult men
with erectile dysfunction.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUWWAUPPUBW
(END) Dow Jones Newswires
May 23, 2022 05:35 ET (09:35 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2023 to May 2024